Comparative transcriptome analyses revealed conserved biological and transcription factor target modules between the zebrafish and human tumors

Zebrafish

Volumn 6, Issue 4, 2009, Pages 425-431

  Ung, Choong Yong ^a   Lam, Siew Hong ^a   Gong, Zhiyuan ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TUMOR MARKER;

ANIMAL; ARTICLE; COMPARATIVE STUDY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; METABOLISM; NEOPLASM; PATHOLOGY; ZEBRA FISH;

ANIMALS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; ZEBRAFISH;

DANIO RERIO;

EID: 74049125233     PISSN: 15458547     EISSN: None     Source Type: Journal    
DOI: 10.1089/zeb.2009.0608     Document Type: Article

References (40)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-13795.
3. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family tree of cancer. Nat Genet 2002;32(Suppl):533-540.
4. Lam SH, Wu YL, Vega VB, Miller LD, Spitsbergen J, Tong Y, et al. Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression. Nat Biotechnol 2006;24:73-75.
5. Lam SH, Gong Z. Modeling liver cancer using zebrafish: a comparative oncogenomics approach. Cell Cycle 2006;5:573-577.
6. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002;13:1929-1939.
7. Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 2004;39:944-953.
8. Chen X, Leung SY, Yuen ST, Chu KM, Ji J, Li R, et al. Variation in gene expression patterns in human gastric cancers. Mol Biol Cell 2003;14:3208-3215.
9. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-826.
10. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-5978.
11. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-13789.
12. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005;102:15545-15550.
13. Feitelson MA, Sun B, Satiroglu Tufan NL, Liu J, Pan J, Lian Z. Genetic mechanisms of hepatocarcinogenesis. Oncogene 2002;21:2593-2604.
14. Xu XR, Huang J, Xu ZG, Qian BZ, Zhu ZD, Yan Q, et al. Insight into hepatocellular carcinogenesis at transcriptome level by comparing gene expression profiles of hepatocellular carcinoma with those of corresponding noncancerous liver. Proc Natl Acad Sci USA 2001;98: 15089-15094.
15. Fang ZH, Han ZC. The transcription factor E2F: a crucial switch in the control of homeostasis and tumorigenesis. Histol Histopathol 2006;21:403-413.
16. Korenjak M, Brehm A. E2F-Rb complexes regulating transcription of genes important for differentiation and development. Curr Opin Genet Dev 2005;15:520-527.
17. Felsher DW, Bradon N. Pharmacological inactivation of MYC for the treatment of cancer. Drug News Perspect 2003;16:370-374.
18. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318:533-538.
19. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986;45:485-495.
20. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-104.
21. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-1117.
22. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 2000;14:2501-2514.
23. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Barrette TR, Ghosh D, Chinnaiyan AM. Mining for regulatory programs in the cancer transcriptome. Nat Genet 2005;37:579-583.
24. Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 2004;4:562-568.
25. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;8: 635-645.
26. Sun A, Bagella L, Tutton S, Romano G, Giordano A. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem 2007;102:1400-1404.
27. Ahlander J, Bosco G. The RB/E2F pathway and regulation of RNA processing. Biochem Biophys Res Commun 2009;384: 280-283.
28. Blais A, Dynlacht BD. E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol 2007;19:658-662.
29. Dang CV. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found Symp Proc 2007;4:35-53.
30. Worku D, Jouhra F, Jiang GW, Patani N, Newbold RF, Mokbel K. Evidence of a tumour suppressive function of E2F1 gene in human breast cancer. Anticancer Res 2008;28: 2135-2139.
31. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: structure, function, and therapeutic implications in cancer biology. Oncogene 2006;25:1125-1142.
32. Castellano G, Torrisi E, Ligresti G, Malaponte G, Militello L, Russo AE, et al. The involvement of the transcription factor Yin Yang 1 in cancer development and progression. Cell Cycle 2009;8:1367-1372.
33. Parija T, Das BR. Involvement of YY1 and its correlation with c-myc in NDEA induced hepatocarcinogenesis, its prevention by d-limonene. Mol Biol Rep 2003;30:41-46.
34. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
35. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000;19:6613-6626.
36. MacDonald G, Stramwasser M, Mueller CR. Characterization of a negative transcriptional element in the BRCA1 promoter. Breast Cancer Res 2007;9:R49-R61.
37. Royuela M, Rodríguez-Berriguete G, Fraile B, Paniagua R. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol 2008;23:1279-1290.
38. Klinge CM. Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem 2008;105:1342-1451.
39. Fajas L, Fruchart JC, Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol 1998;10:165-173.
40. Hahn ME. The aryl hydrocarbon receptor: a comparative perspective. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;121:23-53.